Faes Farma S.A.
ISIN: ES0134950F36 | Ticker: FAE | LEI: 959800FXZQY7U3P1G969
Country: Spain
Founded in 1933, FAES FARMA is a Spanish pharmaceutical company with extensive international experience that researches, produces and markets pharmaceutical products and raw materials, exporting them to many countries.
The identity of the company is defined by an unwavering search of excellence, the constant pursuit of a máximum pharmacological quality of all its products and the consequent effort to always offer highly effective solutions for patients.
FAES FARMA operates in many countries, employing more than 1680 people. Its headquarters, manufacturing and R & D center is located in Leioa (Bizkaia). FAES FARMA has also facilities in Madrid and subsidiaries in Portugal, Laboratorios Vitoria, in Barcelona Diafarm Laboratories and also in Italy, France, Chile, Mexico, Colombia, Peru, Ecuador and Nigeria. FAES FARMA has nutrition and animal health companies (FARM Faes) such as Ingaso Farm and Tecnovit.
1933
Served areaWorldwide
Headcount1,680
HeadquartersAv Autonomia 10, 48940 Leioa – Spain
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | 493,673,000.00 | N/A | 581,517,000.00 | N/A | 645,114,000.00 | N/A | 725,670,000.00 |
| Noncurrent Assets | N/A | 270,684,000.00 | N/A | 291,510,000.00 | N/A | 351,403,000.00 | N/A | 412,459,000.00 |
| Property Plant And Equipment | N/A | 78,703,000.00 | N/A | 91,254,000.00 | N/A | 136,100,000.00 | N/A | 200,141,000.00 |
| Investment Property | N/A | 1,550,000.00 | N/A | 1,550,000.00 | N/A | 1,550,000.00 | N/A | 1,550,000.00 |
| Deferred Tax Assets | N/A | 14,133,000.00 | N/A | 28,854,000.00 | N/A | 26,474,000.00 | N/A | 21,286,000.00 |
| Other Noncurrent Financial Assets | N/A | 460,000.00 | N/A | 338,000.00 | N/A | 990,000.00 | N/A | 5,132,000.00 |
| Current Assets | N/A | 222,989,000.00 | N/A | 290,007,000.00 | N/A | 293,711,000.00 | N/A | 313,211,000.00 |
| Inventories | N/A | 71,454,000.00 | N/A | 91,591,000.00 | N/A | 107,451,000.00 | N/A | 115,000,000.00 |
| Trade And Other Current Receivables | N/A | 97,352,000.00 | N/A | 105,280,000.00 | N/A | 112,852,000.00 | N/A | 114,111,000.00 |
| Other Current Financial Assets | N/A | 1,330,000.00 | N/A | 1,926,000.00 | N/A | 3,154,000.00 | N/A | 17,689,000.00 |
| Cash and cash equivalents | N/A | 52,853,000.00 | 52,853,000.00 | 91,210,000.00 | 91,210,000.00 | 70,254,000.00 | 70,254,000.00 | 66,411,000.00 |
| Equity And Liabilities | N/A | 493,673,000.00 | N/A | 581,517,000.00 | N/A | 645,114,000.00 | N/A | 725,670,000.00 |
| Equity | 360,154,000.00 | 413,654,000.00 | 472,877,000.00 | 472,877,000.00 | 537,348,000.00 | 537,348,000.00 | N/A | 602,279,000.00 |
| Issued Capital | N/A | 27,815,000.00 | N/A | 28,524,000.00 | N/A | 29,742,000.00 | N/A | 31,078,000.00 |
| Retained Earnings | N/A | 90,632,000.00 | N/A | 104,268,000.00 | N/A | 127,012,000.00 | N/A | 147,532,000.00 |
| Share Premium | N/A | 1,460,000.00 | N/A | 1,460,000.00 | N/A | 1,460,000.00 | N/A | 1,460,000.00 |
| Treasury Shares | N/A | 5,264,000.00 | N/A | 5,264,000.00 | N/A | 5,264,000.00 | N/A | 5,264,000.00 |
| Other Reserves | N/A | 298,323,000.00 | N/A | 344,896,000.00 | N/A | 385,922,000.00 | N/A | 442,877,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 412,968,000.00 | N/A | 471,395,000.00 | N/A | 535,810,000.00 | N/A | 601,076,000.00 |
| Noncontrolling Interests | N/A | 686,000.00 | N/A | 1,482,000.00 | N/A | 1,538,000.00 | N/A | 1,203,000.00 |
| Liabilities | N/A | 80,019,000.00 | N/A | 108,640,000.00 | N/A | 107,766,000.00 | N/A | 123,391,000.00 |
| Noncurrent Liabilities | N/A | 7,740,000.00 | N/A | 23,955,000.00 | N/A | 28,459,000.00 | N/A | 28,963,000.00 |
| Noncurrent Provisions | N/A | 683,000.00 | N/A | 803,000.00 | N/A | 957,000.00 | N/A | 1,022,000.00 |
| Noncurrent Government Grants | N/A | 187,000.00 | N/A | 187,000.00 | N/A | 157,000.00 | N/A | 35,000.00 |
| Deferred Tax Liabilities | N/A | N/A | N/A | 17,367,000.00 | N/A | 21,699,000.00 | N/A | 19,742,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 3,569,000.00 | N/A | 3,515,000.00 | N/A | 3,498,000.00 | N/A | 3,767,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | 500,000.00 | N/A | 500,000.00 | N/A | 0.00 | N/A | N/A |
| Current Liabilities | N/A | 72,279,000.00 | N/A | 84,685,000.00 | N/A | 79,307,000.00 | N/A | 94,428,000.00 |
| Current Provisions | N/A | 7,181,000.00 | N/A | 11,241,000.00 | N/A | 7,855,000.00 | N/A | 8,165,000.00 |
| Trade And Other Current Payables | N/A | N/A | N/A | 59,331,000.00 | N/A | 54,082,000.00 | N/A | 55,080,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 51,523,000.00 | N/A | 59,331,000.00 | N/A | N/A | N/A | N/A |
| Current Tax Liabilities Current | N/A | 1,208,000.00 | N/A | 1,243,000.00 | N/A | 1,654,000.00 | N/A | 2,307,000.00 |
| Other Current Financial Liabilities | N/A | 9,664,000.00 | N/A | 10,431,000.00 | N/A | 13,619,000.00 | N/A | 27,108,000.00 |
| Other Current Nonfinancial Liabilities | N/A | 302,000.00 | N/A | 59,000.00 | N/A | 0.00 | N/A | N/A |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 357,398,000.00 | 380,240,000.00 | 398,557,000.00 | 438,754,000.00 |
| Other Income | 25,787,000.00 | 31,247,000.00 | 30,084,000.00 | 22,965,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -3,668,000.00 | -2,211,000.00 | 10,594,000.00 | 7,427,000.00 |
| Raw Materials And Consumables Used | 133,656,000.00 | 142,614,000.00 | 135,566,000.00 | 149,312,000.00 |
| Employee Benefits Expense | 76,313,000.00 | 83,136,000.00 | 85,033,000.00 | 91,201,000.00 |
| Depreciation And Amortisation Expense | N/A | 14,826,000.00 | 17,257,000.00 | 19,271,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 3,972,000.00 | 5,540,000.00 | 3,858,000.00 | 439,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 3,972,000.00 | 5,540,000.00 | 3,858,000.00 | 439,000.00 |
| Other Expense By Nature | 85,374,000.00 | 80,811,000.00 | 83,078,000.00 | 92,586,000.00 |
| Finance Income | 59,000.00 | 156,000.00 | 23,000.00 | 253,000.00 |
| Finance Costs | 743,000.00 | 2,045,000.00 | 312,000.00 | 315,000.00 |
| Profit Loss Before Tax | 74,175,000.00 | 84,882,000.00 | 92,966,000.00 | 101,421,000.00 |
| Income Tax Expense Continuing Operations | 10,149,000.00 | 11,506,000.00 | 10,520,000.00 | 11,919,000.00 |
| Profit Loss From Continuing Operations | N/A | N/A | 82,446,000.00 | 89,502,000.00 |
| Profit (loss) | -64,026,000.00 | -73,376,000.00 | 82,446,000.00 | 89,502,000.00 |
| Profit Loss Attributable To Owners Of Parent | 63,962,000.00 | 72,549,000.00 | 82,390,000.00 | 89,550,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 64,000.00 | 827,000.00 | 56,000.00 | -48,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|---|---|---|
| Profit (loss) | -64,026,000.00 | -73,376,000.00 | N/A | 82,446,000.00 | N/A | 89,502,000.00 | N/A |
| Adjustments For Reconcile Profit Loss | N/A | N/A | N/A | 115,998,000.00 | N/A | 125,184,000.00 | N/A |
| Adjustments For Income Tax Expense | 10,149,000.00 | 11,506,000.00 | N/A | 10,520,000.00 | N/A | 11,919,000.00 | N/A |
| Adjustments For Decrease Increase In Inventories | N/A | 717,000.00 | N/A | -460,000.00 | N/A | 1,420,000.00 | N/A |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 3,972,000.00 | 5,540,000.00 | N/A | 3,399,000.00 | N/A | 0.00 | N/A |
| Adjustments For Provisions | 6,375,000.00 | 6,154,000.00 | N/A | 2,024,000.00 | N/A | 2,655,000.00 | N/A |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 1,653,000.00 | N/A | 50,000.00 | N/A | 52,000.00 | N/A |
| Adjustments For Sharebased Payments | N/A | N/A | N/A | 0.00 | N/A | 146,000.00 | N/A |
| Adjustments For Fair Value Gains Losses | 313,000.00 | 126,000.00 | N/A | 46,000.00 | N/A | 0.00 | N/A |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 0.00 | N/A | 220,000.00 | N/A | 439,000.00 | N/A |
| Other Adjustments To Reconcile Profit Loss | N/A | 0.00 | N/A | -30,000.00 | N/A | -122,000.00 | N/A |
| Adjustments For Reconcile Profit Loss | N/A | N/A | N/A | 115,998,000.00 | N/A | 125,184,000.00 | N/A |
| Cash Flows From Used In Operations | 73,130,000.00 | 84,445,000.00 | N/A | 89,085,000.00 | N/A | 114,182,000.00 | N/A |
| Interest Paid Classified As Operating Activities | -51,000.00 | 266,000.00 | N/A | 216,000.00 | N/A | 263,000.00 | N/A |
| Income Taxes Paid Refund Classified As Operating Activities | -5,494,000.00 | -5,690,000.00 | N/A | -9,224,000.00 | N/A | -7,131,000.00 | N/A |
| Other Inflows Outflows Of Cash Classified As Operating Activities | N/A | 0.00 | N/A | -59,000.00 | N/A | 0.00 | N/A |
| Cash Flows From Used In Operating Activities | 67,585,000.00 | 78,489,000.00 | N/A | 79,645,000.00 | N/A | 106,788,000.00 | N/A |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | 11,630,000.00 | 0.00 | N/A | 23,647,000.00 | N/A | 0.00 | N/A |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 334,000.00 | 385,000.00 | N/A | 404,000.00 | N/A | 7,200,000.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 16,974,000.00 | 20,211,000.00 | N/A | 51,490,000.00 | N/A | 75,216,000.00 | N/A |
| Purchase Of Intangible Assets Classified As Investing Activities | 4,430,000.00 | 5,512,000.00 | N/A | 7,927,000.00 | N/A | 5,732,000.00 | N/A |
| Interest Received Classified As Investing Activities | 59,000.00 | 156,000.00 | N/A | 23,000.00 | N/A | 253,000.00 | N/A |
| Cash Flows From Used In Investing Activities | -34,034,000.00 | -25,782,000.00 | N/A | -83,485,000.00 | N/A | -92,172,000.00 | N/A |
| Payments To Acquire Or Redeem Entitys Shares | 2,834,000.00 | 92,000.00 | N/A | 0.00 | N/A | N/A | N/A |
| Payments Of Other Equity Instruments | N/A | N/A | N/A | 1,947,000.00 | N/A | 2,626,000.00 | N/A |
| Proceeds From Borrowings Classified As Financing Activities | -1,393,000.00 | -600,000.00 | N/A | N/A | N/A | N/A | N/A |
| Repayments Of Borrowings Classified As Financing Activities | 43,922,000.00 | 946,000.00 | N/A | 1,450,000.00 | N/A | 0.00 | N/A |
| Dividends Paid Classified As Financing Activities | 10,338,000.00 | 11,544,000.00 | N/A | 13,719,000.00 | N/A | 18,147,000.00 | N/A |
| Cash Flows From Used In Financing Activities | -56,736,000.00 | -14,350,000.00 | N/A | -17,116,000.00 | N/A | -18,459,000.00 | N/A |
| Cash and cash equivalents | 52,853,000.00 | 91,210,000.00 | 52,853,000.00 | 70,254,000.00 | 91,210,000.00 | 66,411,000.00 | 70,254,000.00 |
Please note that some sums might not add up.
ES0134950F36
LEI959800FXZQY7U3P1G969
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.